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Expression of the ret Proto-oncogene in Human Medullary Thyroid
Carcinomas and Pheochromocytomas of MEN 2A

Akihiro Miya,* Masayuki Yamamoto,* Hideki Morimoto,* Norifumi Tanaka,* Eisei
Shin,* Katsu Karakawa,* Kumao Toyoshima,^ Yukihito Ishizaka,* Takesada Mori,*
and Shin-Ichiro Takai§

We studied the expression of the ret proto-oncogene (proto-ret) in human medullary thyroid
carcinomas (MTCs) and pheochromocytomas of multiple endocrine neoplasia type 2A (MEN 2A) by
Northern blot analysis. E.xpression ofthe normal-sized transcripts was detecied in all 12 MTCs and in
6 of 8 pheochromocytomas. In situ localization of proto-ret mRNA revealed that the signal was
confined to the cytoplasm of MTC cells. By Southern blot analysis neither amplification nor gross
genetic changes of proto-ret were found in the tumors. Although no transcripts were detected in the
normal portion ofthe thyroidfrom one MEN 2 A patient,faint signals were detected in normal adrenal
glands by Northern blot analysis, probably due to minor populations of C-cells and chromaffin cells
in specimens from which MTC and pheochromocytoma might later develop. Proto-ret may play an
important role in differentiation ofa specific cell lineage from neuroectoderm, and it may be involved
in development of MEN 2A tumors. (Henry Ford Hosp Med J 1992;40:215-9]

T

he gene responsible for multiple endocrine neoplasia type
2A (MEN 2A) has been mapped to the pericentromeric region of chromosome 10 by linkage analysis using polymorphic
DNA markers (1-3). The activated ret oncogene was first isolated by DNA transfection of a human T-cell lymphoma DNA
into NIH3T3 cells (4). Two different activated forms of the ret
proto-oncogene, ret (4) and ret-\\ (5), have been reported. The
activation in these cases occurred by the rearrangement ofthe 5'half of proto-ret during the transfection assay. 'Proto-ret was
mapped to chromosome 1 Oqi 1.2 near the probable MEN2A locus by in situ hybridization (6). We have confirmed by linkage
analysis that proto-/ <?r is located near the MEN2A locus (7). Expression of iproto-ret has been examined in human tumor cell
lines and its overexpression was detected in a neuroblastoma
cell line (SK-N-SH), a promyelocytic leukemia cell line (HL60), and a monocytic leukemia cell line (THP-1) (8). Ikeda et al
(9) found that expression of proto-rer was detected in all 11 neuroblastoina cell lines examined. Nagao et al (10) found specific
expression of proto-rermRNA in all 29 neuroblastomas studied.
Moreover, Santoro et al (11) reported that among several normal
and tumorous human tissues, proto-rcf was consistently expressed in pheochromocytomas and medullary thyroid carcinomas (MTCs). MTC, pheochromocytoma, and neuroblastoma
are tumors derived from neural crest. These findings suggest a
possible relationship between activation or overexpression of
proto-rc? and the oncogenic mechanism in MEN 2.
One of the seven MTCs examined by Santoro et al (11) was
from a patient with the MEN 2B .syndrome, while the other six
were of the nonhereditary type. Their report prompted us to
study expression of proto-ret in MTCs and pheochromocyto-
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mas, especially from patients with MEN 2A. Murotani et al (12)
reported that microwave (MW)-fixed tissue samples were applicable to in situ hybridization as well as to the immunohistochemical analysis of the expression of various oncogenes.
In the present study, we report expression of the proto-ret in
the tumors of the MEN 2A syndrome. Moreover, we show the
localization of proto-ret mRNA in MTC cells by in situ hybridization in MW-fixed thyroid tissues using a digoxigenin-labeled
cDNA probe.

Methods
Tbmor samples and normal tissues
Surgical specimens of 12 MTCs (8 from MEN 2A patients
and 4 from nonhereditary patients) and 8 pheochromocytomas
(6 from MEN 2A patients and 2 from nonhereditary patients)
were used. Normal thyroid tissues were nontumorous parts of
thyroid glands resected from MEN 2A patients. Normal adrenal
tissues were obtained from widely resected specimens in the
radical operation for renal cell carcinoma. All samples were frozen immediately and kept at -80 °C until use.
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Northern blot analysis
Total cellular RNA was extracted by the acid guanidium thiocyanate-phenol-chloroform method (13), Total RNA, 20 jig,
was electrophoresed in 1% formaldehyde-agarose denaturing
gel and blotted onto nylon membrane (Hybond-N, Amersham).
Prehybridization was perfonned at 42 °C for 4 hours under stringent conditions (5 x SSPE, 50% formamide), and the membrane
hybridized with the radiolabeled cDNA for 16 hours.
The probe used for detecting proto-ret mRNA was a 0.4 kb
EcoRI-NcoI fragment of rc/-II cDNA, which contained a portion ofthe kinase domain (10). As a control, a complete 2 kb human p-actin cDNA (Clontech Laboratories, Inc., Palo Alto, CA)
was used. Each probe was labeled with [a^-P]dCTP (Amersham, 3,000 Ci/mmoL) to a specific activity of 1-3 x 10^ cpm/
\ig DNA, using a Multiprime Labeling Kit (Amersham). The
membrane was washed in 2 x SSPE, 0.1 x SDS at 42 °C for 15
minutes twice, in 1 x SSPE, 0.1 x SDS at 65 °C for 30 minutes,
and finally in 0.1 x SSPE, 0.1 x SDS at 65 °C for 15 minutes
twice. Blots were exposed to x-ray film at -80 °C with an intensifying screen for 24 to 120 hours.
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Fig 1—Northern blot analysis of proto-rst mRNA in human
MTCs and pheochromocytomas. A) E.xpression in human thyroid tumors. The samples were as follows: follicular adenoma
(lanes 1,2); papillary carcinoma (lanes 3,4); anaplastic carcinoma (lane 5); nonhereditary MTC (lane 6); and MTC from
MEN 2A patient (lane 7).B) The samples were asfollows: pheochromocytoma from MEN 2A patient (lane I ) ; nonhereditary
pheochromocytoma (paraganglioma) (lane 2); MTCs from
MEN 2A patients (lanes 3,4, 5, 6T, 7T, 8T); and nontumorous
thyroid glands (lanes 6N, 7N, 8N). C) The samples were as f o f
lows; normal adrenal gland (lanes 1,2) and pheochromocytoma from MEN 2A patients (lanes 3,4,5).
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Southern blot analysis
High molecular weight DNA was extracted as described previously (14). Five [lg DNA of each sample was digested with
BamHI, electrophoresed in 0.8% agarose gel, and blotted onto
nylon membrane. Hybridization was performed with a 0.6 kb
Sall-BamHI fragment of proto-m cDNA (pN6) as described
previously (15).
In situ hybridization on MW-fixed specimen
Fixation of tissues and preparation of sections—Specimens
obtained at surgery were immediately cut into pieces of about 5
cubic mm. They were fixed by MW irradiation, embedded in
paraffin, and sliced into 4 p,m sections as described by Murotani
etal (12).
Immunohistochemical analysis—One of the serial sections
was stained by the avidin-biotin peroxidase complex (ABC)
method with the murine anti-CEA monoclonal antibody (CM010, Mochida Pharmaceutical Co., Tokyo) (16) to identify foci
of MTC.
Localization of proto-ret mRNA by in situ hybridization—
Sections adjacent to the one for CEA staining were used for in
situ hybridization. A 0.2 kb BamHI fragment of proto-ret cDNA
(pN6) which contained a portion ofthe transmembrane domain
(9) was labeled with digoxigenin (17) by Genius™ Nonradioactive DNA Labeling and Detection Kit (Boehriger Mannheim
Biochemicals) and used as a probe. KS vector (Stratagene, CA),
which was used to subclone proto-ret cDNA, was labeled and
used as a negative control.

Results
Expression of the proto-ret in human MTCs and
pheochromocytomas
We examined expression of proto-rer in various human thyroid tumors, including two follicular adenomas, two papillary
carcinomas, four anaplastic carcinomas, and 12 MTCs. Among
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these tumors, all 12 MTCs expressed the 7.0,6.0,4.5, and 3.9 kb
mRNA as shown in Fig 1, regardless of MEN 2A (Fig 1 A, lane
7; Fig IB, lanes 3, 4, 5, 6T, 7T, 8T) or nonhereditary type (Fig
lA, lane 6). Other types of thyroid tumors (Fig lA, lanes 1-5)
showed no detectable signals of proto-ret transcripts in autoradiogram even after 5-day exposure of the film (data not shown).
We examined expression of proto-ret in pheochromocytomas
of MEN 2A. Proto-ret mRNA was expressed in 6 of 8 pheochromocytomas. Representative results are shown in Fig IB (lane 1)
and Fig IC (lanes 3-5). The two negative cases were MEN 2A
tumors which were the oldest specimens kept for more than five
years. The negative result was probably related to RNA degradation because mRNA of P-actin was degraded in these cases. In
an ectopic pheochromocytoma (paraganglioma) we detected
low expression (Fig IB, lane 2). In three cases of MEN 2A we
could compare the expression of the proto-ret in MTC and in the
normal portion of the thyroid gland, and no expression was detected in the latter (Fig IB, lanes 6N, 7N, 8N). We found only
faint signals of mRNA in normal adrenal glands (Fig IC, lanes
1,2).
In situ localization of the proto-ret mRNA
Localization of proto-ret mRNA in the thyroid gland of one
MEN 2A patient was clearly confined to the cytoplasm of MTC
cells identified imrnunohistochemically on the adjacent section
using anti-CEA monoclonal antibody (Fig 2, left half). Treatment of the sections with RNa.se greatly decreased or abolished
these cytoplasmic signals, and no signals were detected by in
situ hybridization using a nonspecific vector probe instead of
proto-/c/ cDNA (data not shown).
Southern blot analysis of the structure of proto-ret
To examine amplification or gross structural changes in
proto-ret. Southern blot analysis was performed. A single band
of 7.8 kb was detected by BamHI in all MTCs and pheochromocytomas from the MEN 2A patients examined. Neither amplification nor rearrangements were detected in any case (Fig 3).

Discussion
It is generally accepted that growth of a neoplasm results
from the accumulation of several genetic changes in a particular
cell type. These changes could include activation or overexpression of oncogenes or inactivation of one or more tumor-suppressor genes. The predisposing gene for MEN 2A has been mapped
to the pericentromeric region of chromosome 10; however, the
nature of the genetic defect has not yet been defined. It is likely,
however, that other genetic changes besides the MEN 2 locus
will be involved in the oncogenesis of MTC and pheochromocytoma in this disorder. Studies on the loss of heterozygosity in
these two tumors suggest the involvement of putative tumorsuppressor genes on chromosome 1,3, 17, and 22 (18-20). No
specific oncogene has yet been implicated in either MTC or
pheochromocytoma, although there have been reports of myc
expression (21) or ras activation (14) in a few cases.
Our studies have demonstrated expression of the proto-ret
oncogene in 12 MTCs and 6 of 8 pheochromocytomas when an-
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CEA
Fig 2—Left half; Immunohistochemical detection of CEA in
MTC. A small focus of MTC was clearly demonstrated by CEA
staining. Right half: Expression of proto-ret in MTC. Proto-ret
e.xpression in MTC cells was demonstrated by in situ hybridization (ISH). In the normal follicular epithelial cells, no evidence
of hybridization was detectable.
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Fig 3—Southern blot analysis of proto-ret in MTCs and pheochromocytomas from MEN 2A patients. DNA was digested with
BamHI. A 0.6 kb Sall-BamHl fragment ofproto-ret cDNA (pN6)
was used as a probe. The samples were as follows: MTCs (lanes
1-5); pheochromocytomas (lanes 6-10); and placenta DNA, as a
control (lane 11). A single 7.8 kb band was detected from the
MEN 2A tumors.

alyzed by Northem analysis, results in accordance with the data
of Santoro et al (11). These results identify the proto-rer oncogene as a possible candidate oncogene in MTC or pheochromocytoma.
To understand the role of proto-ret in oncogenesis, the expression of proto-ret in normal tissues must be studied. Santoro
et al (11) did not find proto-/-e? expressed in normal human meninges, testis, ovary, adult brain, fetal brain, pancreas, liver, or
placenta. However, they found low levels of expression in normal thyroid using poly(A)+mRNA. We studied nontumorous
portions of the thyroid gland from MEN 2A patients and found
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Table
Ttimors of Neuroectodermal Origin

Positive

Expression of Proto-ret
Negative

Positive

MTC
Pheochromocytoma

Meningioma
Ewing's Sarcoma

Negative

Neuroblastoma

Glioma

Unkno-wn

Schwannoma

Melanoma

Expression of
Proto-dbl

that RNA transcripts of proto-ref were not detectable by Northem blot analysis using total RNA. In our study, normal thyroid
follicular cells were not stained by in situ hybridization (perhaps
low levels are not stained by in situ hybridization). It is possible
that low levels of proto-ret expression in the normal thyroid detected by Santoro et al (11) are due to the expression in C-cells in
the specimen. The discrepancy between our results and those of
Santoro et al (11) may have resulted from the different detection
methods used.
The faint signal observed in Northem blot analysis of normal
adrenal gland in our study may be related to dilution by a large
amount of adrenal cortex which does not express the proto-ret
oncogene. Prior studies have demonstrated a corticomeduUary
ratio of 6-10:1 in the normal adrenal gland (22). The difficulty of
separation of adrenal cortex from medulla led us to examine the
adrenal glands as a whole for proto-re? oncogene expression. In
future studies it wdl be important to study this question by in
situ hybridization techniques.
Human tumors in which expression of proto-rer has been described are generally of neuroectodermal origin. These tumors
include neuroblastomas (9,10), MTCs (11, and the present paper), pheochromocytoma (11, and the present paper), and malignant Schwannomas (23). There are, however, other tumors of
neuroectodermal origin such as melanomas, gliomas, and Ewing's sarcoma which do not express the proto-rer oncogene
(11,24).
Recendy, de Franciscis et al (25) reported expression of the
dbl proto-oncogene (proto-dbl) in some tumors of neuroectodermal origin. These tumors include meningiomas, Ewing's
sarcomas, MTCs, and pheochromocytomas. Neuroblastomas
and gliomas do not express dbl (25). One could conclude from
these studies that expression of dbl is important in differentiation of certain cell types from neuroectoderm; however, it cannot be the MEN 2 predisposition gene because of the dbl location on the X chromosome (26).
We would like to propose a classification of tumors of neuroectodermal origin into four classes as outlined in the Table:
group 1 = cells requiring expression of proto-rf ? for differentiation, group 2 = cells requiring expression of proto-dbl for differentiation, group 3 = cells requiring expression of both proto-re/
and proto-dbl for differentiation, and group 4 = cells requiring
neither for differentiation.
MTC and pheochromocytoma, the two main component tumors of the MEN 2 syndrome, appear to belong to the class of

218 Henry Ford Hosp Med J^Vol 40. Nos 3 & 4. 1992

Unknown

Ganglioneuroma
Neuroepithelioma

neuroectodermal cells which require expression of proto-ret artd
proto-dbl for differentiation. We hypothesize that mutation of
the MEN 2 gene might initiate transformation only in those cells
in which both proto-rer and proto-dbl are expressed. This hypothesis would provide an explanation for organ specificity of
tumors in MEN 2A.
It will be important and interesting to study the stmctural alteration of the proto-rer oncogene in MTC to more fully define
the role of this gene in the development of tumors associated
with MEN 2.
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